A Time-Motion Observational Study of Clinic Staff: Administration of Pegfilgrastim Primary Prophylaxis Via Next-Day Manual Injection and On-Body Injector (OBI)

Abstract

Most SCCHN patients are referred to community medical oncologists by primary care physicians or surgeons; it was estimated that two-thirds of presenting patients are newly diagnosed and that one-third have relapsed. None of the participants routinely test, document, or alter treatment for suspected HPV etiology. HPV positivity is clinically suspected based on a limited smoking and alcohol consumption history, younger age, good performance status, and locally advanced disease. Concurrent platinum-based chemoradiotherapy is standard of care for most patients with < 10% undergoing subsequent surgery. Ancillary services (dental work, central line placement, triple endoscopy, percutaneous endoscopic gastrostomy) do not impede chemotherapy initiation. Positron emission tomography (PET) is the standard for staging with restaging PET performed 3 months after last radiation dose. IO availability appears to have resulted in eliminating the need for a repeat PET at 6-months if a 3-month PET is positive allowing patients to initiate treatment earlier. ConClusions: The increasing role of HPV in SCCHN has had minimal impact on treatment paradigms, whereas the availability of new treatment options, such as IO, has significantly altered the course of the SCCHN patient journey.

Economic Analysis on Adoption of Biosimilar Granulocyte Colony-Stimulating Factors in Patients With Nonmyeloid Cancer at Risk of Febrile Neutropenia Within the Oncology Care Model Framework

“…24 Drug administration costs were based on physician fee schedules for administration costs of G-SCFs, published in April 2020, by the Centers for Medicare and Medicaid Services. 25 Nursing labor costs were calculated by multiplying the number of observed nursing hours needed to administer each drug 26 with published national average nurse wages in 2020. Finally, HCRU costs associated with FN were estimated based on average costs reported in the literature.…”

“…Finally, HCRU costs associated with FN were estimated based on average costs reported in the literature. 26 , 27 The proportion of patients who received prophylactic use of G-CSF, but still experienced FN events, was estimated. Costs of such FN events that would result in (1) emergency department (ED) visits with hospitalization, (2) ED visit without hospitalization, (3) outpatient visit with hospitalization, and (4) outpatient visit without hospitalization were estimated.…”